Interventions create value only when they reflect the priorities and constraints of the people expected to use, deliver, or fund them. I use preference-elicitation methods, including discrete-choice experiments, to examine how patients, providers, payers, and other stakeholders weigh benefits, risks, costs, convenience, and access. By identifying preference heterogeneity and potential barriers to adoption, this research informs program design, implementation strategies, and decisions about which solutions are most likely to be accepted and sustained.

Selected Publications:

1. Saldarriaga EM, Hauber B, Tran J, et al. Heterogeneity of patient preferences for long-acting HIV treatment among people with HIV in Kenya. BMC Infect Dis. Published online July 10, 2026. doi:10.1186/s12879-026-13927-x
2. Saldarriaga EM, Chen Y, Montaño MA, Thuo N, Kiptinness C, Terris-Prestholt F, et al. Preferences for pre-exposure prophylaxis delivery via online pharmacy among potential users in Kenya: a discrete choice experiment. J Int AIDS Soc. 2024 Oct;27(10):e26356.
3. Graham SM, Barthold D, Hauber B, Brah AT, Saldarriaga E, Collier AC, et al. U.S. patient preferences for long-acting HIV treatment: a discrete choice experiment. J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26099.
4. Saldarriaga EM, Hauber B, Carlson JJ, Barthold D, Veenstra DL, Devine B. Assessing Payers’ Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment. Value Health. 2022 Mar;25(3):443–50.